TAIKO PHARMACEUTICAL CO., LTD. Logo

TAIKO PHARMACEUTICAL CO., LTD.

Manufactures OTC gastrointestinal medicine and leading infection control products.

4574 | T

Overview

Corporate Details

ISIN(s):
JP3442200006
LEI:
Country:
Japan
Address:
吹田市内本町三丁目34番14号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Taiko Pharmaceutical Co., Ltd. is a manufacturer and distributor specializing in pharmaceuticals and infection control products. The company operates through three primary business segments: Pharmaceutical, Infection Control, and Others. Its Pharmaceutical division is centered on its flagship product, Seirogan, an over-the-counter gastrointestinal medication with a history of over 100 years, used for treating symptoms like diarrhea and loose stools. The Infection Control division, a significant contributor to company revenue, develops and markets products including a leading brand of airborne disinfectants. The company is engaged in ongoing research and development to support its product lines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:35
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-08-08 08:34
Interim Report
半期報告書-第80期(2025/01/01-2025/12/31)
Japanese 197.8 KB
2025-04-01 08:45
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2025-03-28 07:36
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2025-03-28 07:35
Governance Information
内部統制報告書-第79期(2024/01/01-2024/12/31)
Japanese 22.1 KB
2025-03-28 07:33
Registration Form
確認書
Japanese 8.1 KB
2025-03-28 07:32
Annual Report
有価証券報告書-第79期(2024/01/01-2024/12/31)
Japanese 1011.8 KB
2024-08-09 08:34
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-08-09 08:33
Interim Report
半期報告書-第79期(2024/01/01-2024/12/31)
Japanese 210.9 KB
2024-05-10 08:37
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-05-10 08:35
Quarterly Report
四半期報告書-第79期第1四半期(2024/01/01-2024/03/31)
Japanese 164.9 KB
2024-04-01 08:14
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2024-03-28 07:30
Governance Information
内部統制報告書-第78期(2023/01/01-2023/12/31)
Japanese 22.1 KB
2024-03-28 07:28
Registration Form
確認書
Japanese 8.1 KB
2024-03-28 07:26
Annual Report
有価証券報告書-第78期(2023/01/01-2023/12/31)
Japanese 1.1 MB

Automate Your Workflow. Get a real-time feed of all TAIKO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAIKO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAIKO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America SPRY
ARTELO BIOSCIENCES, INC. Logo
Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.
United States of America ARTL
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America ARTV
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Ascendis Pharma A/S Logo
Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.
United States of America ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.
United States of America AAPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.